Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC


Herbst R. S. , Giaccone G., de Marinis F., Reinmuth N., Vergnenegre A., Barrios C. H. , ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.383, no.14, pp.1328-1339, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 383 Issue: 14
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa1917346
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.1328-1339
  • Istanbul University Affiliated: No

Abstract

BackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.